Stock listing
NASDAQ:IBRX ImmunityBio, Inc. Stock
Home listing (NASDAQ) of ImmunityBio, Inc.
Follow ImmunityBio, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:IBRX
$6.02 USD -0.68 (-10.1%)
Close on Nov 20, 2026
- Day range
- $6.00 – $6.53 USDNov 20, 2026
- Volume
- 10.57M sharesNov 20, 2026
- Market cap
- $6.40B USDAt the close on Nov 20, 2026 · price × 1.06B shares outstanding
- 52-week range
- $1.95 – $12.43 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $108.3M USDMedian day 11.06M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:IBRX · Home | $6.02 USD | -0.68 (-10.1%) | 10,565,228 | $6.41 | $6.53 | $6.00 | $6.70 | Close on Nov 20, 2026 |
| Frankfurt:26CA | €5.51 EUR | -0.45 (-7.6%) | — | €5.86 | €5.86 | €5.51 | €5.96 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IBRX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $6.02 | -0.68 | -10.1% | $6.41 | $6.53 | $6.00 | 10,565,228 | |
| $6.70 | +0.44 | +7.0% | $6.255 | $6.78 | $6.12 | 15,772,893 | |
| $6.26 | +0.28 | +4.7% | $6.13 | $6.38 | $6.08 | 11,471,950 | |
| $5.98 | -0.04 | -0.7% | $5.87 | $6.14 | $5.76 | 12,799,375 | |
| $6.02 | -0.05 | -0.8% | $6.09 | $6.17 | $5.83 | 13,302,272 | |
| $6.07 | -0.60 | -9.0% | $6.45 | $6.50 | $6.00 | 20,957,501 | |
| $6.67 | -0.075 | -1.1% | $6.847 | $6.847 | $6.51 | 11,934,176 | |
| $6.745 | -0.365 | -5.1% | $6.97 | $7.27 | $6.61 | 20,007,921 | |
| $7.11 | -1.525 | -17.7% | $7.23 | $7.345 | $6.36 | 44,767,080 | |
| $8.635 | +0.625 | +7.8% | $8.17 | $8.69 | $7.881 | 9,215,309 | |
| $8.01 | -0.92 | -10.3% | $8.78 | $8.79 | $8.00 | 12,504,489 | |
| $8.93 | +0.64 | +7.7% | $8.42 | $8.95 | $8.205 | 9,706,618 | |
| $8.29 | +0.34 | +4.3% | $8.00 | $8.425 | $7.97 | 6,175,086 | |
| $7.95 | -0.34 | -4.1% | $8.32 | $8.39 | $7.93 | 9,031,814 | |
| $8.29 | -0.45 | -5.1% | $8.48 | $8.72 | $8.122 | 8,911,096 | |
| $8.74 | -0.07 | -0.8% | $8.75 | $8.935 | $8.56 | 7,113,047 | |
| $8.81 | +0.18 | +2.1% | $8.66 | $8.83 | $8.48 | 7,136,872 | |
| $8.63 | +0.82 | +10.5% | $7.84 | $8.685 | $7.765 | 10,486,483 | |
| $7.81 | -0.41 | -5.0% | $8.255 | $8.28 | $7.75 | 10,960,202 | |
| $8.22 | -0.09 | -1.1% | $8.22 | $8.355 | $8.05 | 5,922,752 | |
| $8.31 | -0.33 | -3.8% | $8.51 | $8.84 | $8.02 | 12,731,345 | |
| $8.64 | -0.13 | -1.5% | $8.88 | $8.99 | $8.32 | 11,462,803 | |
| $8.77 | +0.35 | +4.2% | $8.31 | $8.90 | $8.11 | 13,971,629 | |
| $8.42 | -0.76 | -8.3% | $9.19 | $9.697 | $8.31 | 19,509,986 | |
| $9.18 | -0.82 | -8.2% | $10.02 | $10.02 | $9.02 | 21,485,000 | |
| $10.00 | +0.09 | +0.9% | $10.20 | $10.50 | $9.815 | 20,010,100 | |
| $9.91 | +0.11 | +1.1% | $9.69 | $10.46 | $9.35 | 30,228,600 | |
| $9.80 | -0.32 | -3.2% | $10.00 | $10.06 | $9.56 | 11,604,000 | |
| $10.12 | -0.39 | -3.7% | $10.59 | $10.62 | $10.05 | 11,057,100 | |
| $10.51 | +0.60 | +6.1% | $9.95 | $10.80 | $9.87 | 18,657,500 | |
| $9.91 | +0.16 | +1.6% | $9.63 | $10.05 | $9.43 | 10,492,100 | |
| $9.75 | +0.06 | +0.6% | $9.50 | $9.93 | $9.33 | 11,780,000 | |
| $9.69 | -0.69 | -6.6% | $10.33 | $10.36 | $9.61 | 16,887,000 | |
| $10.38 | +0.095 | +0.9% | $10.76 | $10.81 | $10.13 | 16,866,900 | |
| $10.29 | +1.005 | +10.8% | $9.39 | $10.55 | $9.39 | 31,251,600 | |
| $9.28 | -0.16 | -1.7% | $9.28 | $9.40 | $9.07 | 12,313,700 | |
| $9.44 | +0.61 | +6.9% | $8.92 | $10.09 | $8.90 | 27,286,800 | |
| $8.83 | +0.31 | +3.6% | $8.52 | $8.88 | $8.52 | 8,366,600 | |
| $8.52 | +0.08 | +0.9% | $8.39 | $8.979 | $8.26 | 10,413,600 | |
| $8.44 | -0.20 | -2.3% | $8.76 | $8.84 | $8.41 | 5,819,400 | |
| $8.64 | +0.01 | +0.1% | $8.50 | $8.675 | $8.31 | 8,980,000 | |
| $8.63 | -0.66 | -7.1% | $9.26 | $9.29 | $8.60 | 13,954,500 | |
| $9.29 | +0.84 | +9.9% | $8.45 | $9.48 | $8.37 | 21,133,200 | |
| $8.45 | -0.03 | -0.4% | $8.72 | $8.87 | $8.26 | 12,238,200 | |
| $8.48 | +0.02 | +0.2% | $8.46 | $8.53 | $8.20 | 18,428,900 | |
| $8.46 | +0.55 | +7.0% | $8.14 | $8.80 | $8.12 | 19,159,300 | |
| $7.91 | -0.23 | -2.8% | $8.135 | $8.30 | $7.76 | 9,205,000 | |
| $8.14 | -0.23 | -2.7% | $8.32 | $8.34 | $7.85 | 8,949,300 | |
| $8.37 | +0.46 | +5.8% | $7.89 | $8.40 | $7.87 | 9,158,300 | |
| $7.91 | +0.19 | +2.5% | $7.80 | $8.345 | $7.80 | 12,468,800 | |
| $7.72 | -0.34 | -4.2% | $7.87 | $7.89 | $7.64 | 8,797,200 | |
| $8.06 | -0.23 | -2.8% | $8.22 | $8.36 | $7.875 | 9,485,900 | |
| $8.29 | +0.21 | +2.6% | $8.00 | $8.37 | $7.93 | 7,735,300 | |
| $8.08 | -0.11 | -1.3% | $8.08 | $8.24 | $8.01 | 4,324,700 | |
| $8.19 | +0.24 | +3.0% | $8.00 | $8.21 | $7.88 | 5,271,800 | |
| $7.95 | +0.08 | +1.0% | $7.945 | $8.28 | $7.755 | 7,228,300 | |
| $7.87 | -0.08 | -1.0% | $7.82 | $7.99 | $7.73 | 6,460,300 | |
| $7.95 | -0.10 | -1.2% | $7.88 | $8.02 | $7.84 | 6,873,400 | |
| $8.05 | -0.35 | -4.2% | $8.31 | $8.32 | $7.945 | 7,980,000 | |
| $8.40 | +0.15 | +1.8% | $8.24 | $8.76 | $8.18 | 12,311,500 | |
| $8.25 | +0.06 | +0.7% | $8.17 | $8.40 | $8.07 | 9,446,500 | |
| $8.19 | +0.61 | +8.0% | $7.69 | $8.23 | $7.68 | 11,547,390 | |
| $7.58 | -0.21 | -2.7% | $7.68 | $7.72 | $7.46 | 5,671,527 | |
| $7.79 | -0.05 | -0.6% | $7.85 | $7.95 | $7.60 | 7,619,700 | |
| $7.84 | -0.29 | -3.6% | $7.90 | $8.00 | $7.74 | 8,099,200 |
- Ticker
- NASDAQ:IBRX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
ImmunityBio Named No. 2 Fastest-Growing Technology Company in North America on the 2026 Deloitte Technology Fast 500™
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 33 slides
Latest news
ImmunityBio Named No. 2 Fastest-Growing Technology Company in North America on the 2026 Deloitte Technology Fast 500™
Nov 19, 2026
Closed $6.02 (-10.1%) on Nov 20, 2026
New U.S. Survey of Military Service Members and Veterans with Non-Muscle Invasive Bladder Cancer Reveals 53% Were Diagnosed at Age 50 or Younger and Barriers to Care
Nov 11, 2026
Closed $6.67 (-1.1%) on Nov 11, 2026
ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026
Nov 10, 2026
Closed $6.67 (-1.1%) on Nov 11, 2026
ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million
Nov 9, 2026
Closed $7.11 (-17.7%) on Nov 9, 2026
ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
Nov 9, 2026
Closed $7.11 (-17.7%) on Nov 9, 2026
ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial
Nov 9, 2026
Closed $7.11 (-17.7%) on Nov 9, 2026
ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer
Oct 21, 2026
Closed $8.64 (-1.5%) on Oct 21, 2026
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors
Oct 16, 2026
Closed $9.18 (-8.2%) on Oct 16, 2026
FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
Oct 14, 2026
Closed $10.00 (+0.9%) on Oct 15, 2026
ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium
Oct 8, 2026
Closed $9.91 (+1.6%) on Oct 8, 2026
ImmunityBio, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 54 in the last 12 months · 210 in all · newest Nov 19, 2026 · oldest 2019
- Decks
- 10 decks · latest August 2026
Where ImmunityBio, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:IBRX · Home listing · This page | NASDAQ | United States | USD |
| gettex:26CA | gettex | Germany | EUR |
| LS Exchange:A2QQ2E | LS Exchange | Germany | EUR |
| Tradegate:26CA | Tradegate | Germany | EUR |
| BOATS:IBRX | BOATS | United States | USD |
| Frankfurt:26CA | Frankfurt | Germany | EUR |
| Lang & Schwarz:A2QQ2E | Lang & Schwarz | Germany | EUR |
| Dusseldorf:26CA | Dusseldorf | Germany | EUR |
| Stuttgart:26CA | Stuttgart | Germany | EUR |
| Munich:26CA | Munich | Germany | EUR |
| Hamburg:26CA | Hamburg | Germany | EUR |
| Hanover:26CA | Hanover | Germany | EUR |
| Xetra:26CA | Xetra | Germany | EUR |
| BMV:IBRX | BMV | Mexico | MXN |
Valuation
EV/sales 33.4× against a median of 56.2×: 4th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $6.10B USD
- P/E
- Loss
- EV/sales
- 33.4×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 96.7%
- Operating margin
- −150.2%
- Net margin
- −607.8%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.50
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| ImmunityBio, Inc. · NASDAQ:IBRX | US$6.40B | US$6.10B | n/a | 33.4× | n/a | n/a | −607.8% | n/a | 1.50 |
| CG Oncology, Inc. · NASDAQ:CGON | US$7.10B | US$6.12B | n/a | 992× | n/a | 7.2× | n/a | 0.0× | 0.83 |
| Cytokinetics, Incorporated · NASDAQ:CYTK | US$7.07B | US$6.36B | n/a | 56.2× | n/a | n/a | −686.6% | n/a | 0.93 |
| Axsome Therapeutics, Inc. · NASDAQ:AXSM | US$6.80B | US$6.68B | n/a | 7.7× | n/a | 64.5× | −18.2% | 1.8× | 0.69 |
| Akeso, Inc. · HKEX:9926 | US$6.66B | US$6.04B | n/a | 13.5× | n/a | 5.2× | −36.4% | 0.6× | n/a |
| Immunovant, Inc. · NASDAQ:IMVT | US$6.57B | US$5.85B | n/a | 825× | n/a | 10.0× | n/a | 0.0× | 1.46 |
| Oruka Therapeutics, Inc. · NASDAQ:ORKA | US$6.50B | US$5.58B | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.30 |
| Kodiak Sciences Inc · NASDAQ:KOD | US$6.35B | US$6.31B | n/a | n/a | n/a | 505× | n/a | 3.7× | 1.58 |
| Abivax SA · EURONEXT:ABVX | US$6.05B | US$5.60B | n/a | n/a | n/a | 15.1× | n/a | 0.0× | n/a |
| Scholar Rock Holding Corporation · NASDAQ:SRRK | US$5.87B | US$5.65B | n/a | 9,921× | n/a | 34.8× | n/a | 1.2× | 0.91 |
| Arrowhead Pharmaceuticals, Inc. · NASDAQ:ARWR | US$5.85B | US$4.66B | n/a | 10.3× | n/a | 116× | −160.6% | 0.0× | 1.34 |
| Median of the others | US$6.54B | US$5.95B | 56.2× | 15.1× | −98.5% | 0.0× | 1.12 |
Forecasts
3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 14.25 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.93 · 1 analyst
- Revenue, year to Dec 2026
- 201.8M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Rich Adcock | President & Chief Executive Officer |
| David Sachs | Chief Financial Officer |
| Hemanth Ramaprakash | Investor Relations |
| Bruce Brown | Senior Vice President, Medical Affairs |
| Charles G. Garlisi | Senior Vice President, Regulatory Affairs |
| Elizabeth Gabitzsch | Senior Vice President, Product Development & Vaccine Programs |
| Emily Arison | Senior Vice President of Human Resources |
| Manju Saxena | Senior Vice President of Product Development, Cell Therapy Program |
| Barry Simon | Chief Corporate Affairs Officer |
| Enrique Diloné | Chief Technology Officer |
| Leonard S. Sender | Chief Medical Officer, Liquid Tumors & Cell Therapy |
| Matthew Hilman | Vice President US Commercial – Urologic Oncology |
| Patrick Soon-Shiong | Executive Chairman of the Board |
| Regan Lauer | Chief Accounting Officer |
| Sandeep Bobby Reddy | Chief Medical Officer |
| Sarah Singleton | Chief Communications Officer & Head of Patient Advocacy |
Board
| Director | Role |
|---|---|
| Jim Yong Kim | Vice Chairman |
| Patrick Soon-Shiong | Executive Chairman of the Board |
| Bruce Wendel | |
| Cheryl Cohen | |
| Christobel Selecky | |
| Linda Maxwell | |
| Michael Blaszyk | |
| Wesley Clark |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · Before open | −17.7% |
| Q2 2026 | Aug 4, 2026 · Before open | −2.8% |
| Q1 2026 | May 7, 2026 · Before open | −7.4% |
| Q4 2025 | Mar 3, 2026 | −13.8% |
| Q3 2025 | Nov 4, 2025 · After close | +3.4% |
| Q2 2025 | Aug 5, 2025 · Before open | 0.0% |
| Q1 2025 | May 7, 2025 · After close | +10.6% |
| Q4 2024 | Mar 3, 2025 · Before open | −13.4% |
| Q3 2024 | Nov 12, 2024 · Before open | −9.2% |
| Q2 2024 | Aug 12, 2024 · Before open | −2.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | +0.7% |
| Q4 2023 | Mar 19, 2024 · After close | +10.3% |
| Q3 2023 | Nov 9, 2023 · Before open | −17.1% |
| Q2 2023 | Aug 8, 2023 · After close | −10.2% |
| Q1 2023 | May 11, 2023 · Before open | −55.1% |
| Q4 2022 | Mar 1, 2023 · After close | −10.6% |
| Q3 2022 | Nov 9, 2022 · Before open | −10.7% |
| Q2 2022 | Aug 8, 2022 · After close | −2.9% |
| Q1 2022 | May 10, 2022 · After close | −22.3% |
| Q4 2021 | Mar 1, 2022 · After close | −1.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 33 slides | August 2026 |
| Milken Institute Presentation 2026 | Conference | 67 slides | Feb 24, 2026 |
| Investor Presentation (November 2022) | Investor deck | 30 slides | Nov 15, 2022 |
| Jefferies Healthcare Conference 2022 | Conference | 32 slides | Jun 10, 2022 |
| Investor Presentation (June 2021) | Investor deck | 58 slides | Jun 4, 2021 |
| Investor Presentation (March 2021) | Investor deck | 45 slides | Mar 17, 2021 |
| 39th Annual JP Morgan Healthcare Conference 2021 | Conference | 35 slides | Jan 13, 2021 |
| NantKwest — Merger or Acquisition (December 2020) | Merger or acquisition | 31 slides | Dec 21, 2020 |
| LifeSci Advisors Investor Call, May 27, 2020 | Conference | 18 slides | May 27, 2020 |
| NantKwest — Investor Day (December 2019) | Investor day | 111 slides | Dec 2, 2019 |
Financings
| Raise | Date |
|---|---|
| Registered direct offering of common stock and warrants Announced: about US$80M · Piper Sandler & Co. Dealers: Piper Sandler & Co. (lead) Use of proceeds: Further working capital and support for ongoing business operations | Jul 25, 2025 |
| Registered direct offering of common stock and warrants Announced: about US$75M · warrants for the purchase of additional shares of common stock; if fully exercised,… Buyers: single institutional investor Use of proceeds: Working capital and ongoing business operations | Apr 8, 2025 |
| Public offering of common stock Update: about US$100M · US$3 a share · Jefferies +4 Dealers: Jefferies (co-lead), Piper Sandler (co-lead), BTIG (co-lead), H.C. Wainwright & Co. (co-lead), D. Boral Capital Use of proceeds: Commercialization of ANKTIVA for bladder cancer, trials in BCG-naive NMIBC and NSCLC, R&D, working capital and general corporate purposes | Dec 11, 2024 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as NantKwest, Inc. Priced at US$25.00 a share on Jul 27, 2015.
- Price
- US$25.00 a share
- Shares offered
- 8,288,000 shares of common stock
- Offering size
- US$207.2 million
- Underwriters' option
- Up to 1,243,200 more shares
- Underwriters
- BofA Merrill Lynch, Citigroup, Jefferies, Piper Jaffray, MLV & Co. · In the order on the cover
- Shares delivered
- On or about Jul 31, 2015
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 14, 2015 |
| Filed publicly | Jun 19, 2015 |
| Amended 6 times | Newest Jul 27, 2015 |
| Shares registered with an exchange | Jul 20, 2015 |
| Declared effective by the SEC | Jul 27, 2015 |
| Final prospectus, with the price | Jul 29, 2015 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 29, 2015 |
| EFFECT · Notice that a registration is effective | Jul 27, 2015 |
| S-1MEF · Registration of more shares for the same offering | Jul 27, 2015 |
| S-1/A · Registration statement, amended | Jul 27, 2015 |
| S-1/A · Registration statement, amended | Jul 27, 2015 |
| CERTNAS · Nasdaq's certificate of listing | Jul 24, 2015 |
| CORRESP · Letter to the SEC | Jul 24, 2015 |
| CORRESP · Letter to the SEC | Jul 24, 2015 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 20, 2015 |
| S-1/A · Registration statement, amended | Jul 16, 2015 |
All 23 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jul 15, 2015 |
| S-1/A · Registration statement, amended | Jul 15, 2015 |
| CORRESP · Letter to the SEC | Jul 13, 2015 |
| S-1/A · Registration statement, amended | Jul 13, 2015 |
| UPLOAD · Letter from the SEC | Jul 10, 2015 |
| CORRESP · Letter to the SEC | Jul 6, 2015 |
| CORRESP · Letter to the SEC | Jul 2, 2015 |
| S-1/A · Registration statement, amended | Jul 2, 2015 |
| UPLOAD · Letter from the SEC | Jun 26, 2015 |
| CORRESP · Letter to the SEC | Jun 19, 2015 |
| S-1 · Registration statement | Jun 19, 2015 |
| UPLOAD · Letter from the SEC | Jun 10, 2015 |
| DRS · Draft registration statement | May 14, 2015 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 29, 2015
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 113.3M | 14.7M | 622.0K | 240.0K | 934.0K | 605.0K | 2.20M | 47.0K | 45.0K | 44.0K |
| Cost of revenue | 753.0K | 0 | 0 | 0 | 9.15M | 9.01M | -3.11M | |||
| Gross profit | 112.5M | 14.7M | 622.0K | 240.0K | 934.0K | 605.0K | -8.97M | 3.16M | 45.0K | 44.0K |
| Research and development | 207.9M | 190.1M | 232.4M | 248.1M | 196.0M | 139.5M | 112.0M | 55.7M | 42.0M | 29.2M |
| Selling, general and administrative | 150.0M | 168.8M | 129.6M | 102.7M | 135.3M | 71.3M | 46.5M | 42.7M | 57.1M | 95.4M |
| Operating income | -256.0M | -344.2M | -362.3M | -351.3M | -330.3M | -220.9M | -156.3M | -98.4M | -99.1M | -124.5M |
| Depreciation and amortization | 15.5M | 17.6M | 18.5M | 18.3M | 14.2M | 12.7M | 14.0M | 9.55M | 5.57M | 3.61M |
| EBITDA | -240.5M | -326.6M | -343.7M | -333.0M | -316.0M | -208.1M | -142.2M | -88.8M | -93.6M | -120.9M |
| Interest expense | 60.9M | 114.6M | 128.8M | 63.5M | 14.8M | 9.07M | 5.92M | 433.0K | 618.0K | 66.0K |
| Income before tax | -351.6M | -413.6M | -583.9M | -417.3M | -349.8M | -226.0M | -160.3M | -96.7M | -96.9M | -121.4M |
| Income tax | -135.0K | 0 | -40.0K | 34.0K | 9.00K | -1.85M | -105.0K | -503.0K | -493.0K | -572.0K |
| Net income | -351.4M | -413.6M | -583.2M | -416.6M | -346.8M | -221.9M | -157.8M | -96.2M | -96.4M | -120.8M |
| Earnings per share, basic | -0.38 | -0.59 | -1.15 | -1.04 | -0.89 | -0.59 | -0.43 | -1.22 | -1.20 | -1.47 |
| Earnings per share, diluted | -0.38 | -0.62 | -1.15 | -1.04 | -0.89 | -0.59 | -0.43 | -1.22 | -1.20 | -1.47 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 88.3M | 143.4M | 265.5M | 104.6M | 181.1M | 34.9M | 75.8M | 16.8M | 23.9M | 8.08M |
| Short-term investments | 154.5M | 6.38M | 1.01M | 2.54M | 136.0M | 61.1M | 36.1M | 57.3M | 104.3M | 190.8M |
| Receivables | 42.6M | 2.36M | 0 | 1.89M | 1.33M | 2.00M | 303.0K | 12.2M | 1.26M | 2.67M |
| Inventory | 910.0K | 8.27M | 0 | 26.4M | 1 | |||||
| Current assets | 314.9M | 184.6M | 294.1M | 140.6M | 334.3M | 111.7M | 55.8M | 88.8M | 132.5M | 205.1M |
| Property, plant and equipment | 114.3M | 137.1M | 146.1M | 143.7M | 82.9M | 72.5M | 60.5M | 76.9M | 76.7M | 18.9M |
| Goodwill | 910.0K | 910.0K | ||||||||
| Total assets | 501.9M | 382.9M | 504.5M | 362.4M | 468.9M | 221.4M | 143.1M | 181.9M | 250.4M | 317.5M |
| Accounts payable | 6.98M | 6.72M | 9.20M | 21.0M | 11.4M | 11.5M | 1.75M | 2.79M | 5.87M | 4.04M |
| Current liabilities | 61.8M | 54.9M | 58.3M | 500.9M | 369.0M | 68.1M | 11.6M | 27.3M | 20.9M | 12.6M |
| Long-term debt | 477.1M | 461.9M | 681.5M | 241.3M | 306.3M | 254.4M | ||||
| Total debt | 878.1M | 504.2M | 726.7M | 723.8M | 645.7M | 275.5M | 14.8M | 6.91M | 7.27M | 8.21M |
| Total liabilities | 1.00B | 871.1M | 1.09B | 812.2M | 712.8M | 339.9M | 22.4M | 35.9M | 31.6M | 24.1M |
| Shareholders' equity | -500.5M | -489.1M | -587.0M | -447.3M | -242.2M | -119.8M | 120.7M | 146.0M | 218.8M | 293.4M |
| Shares outstanding | 1.01B | 852.9M | 670.9M | 421.6M | 397.8M | 382.2M | 98.5M | 79.1M | 79.0M | 82.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -304.9M | -391.2M | -366.8M | -337.5M | -274.4M | -171.7M | -152.1M | -63.4M | -48.8M | -38.6M |
| Capital spending | -3.85M | -6.89M | -30.6M | -78.2M | -33.6M | -1.67M | -4.29M | -13.1M | -34.8M | -6.56M |
| Free cash flow | -308.8M | -398.1M | -397.3M | -415.7M | -308.0M | -173.4M | -156.4M | -76.5M | -83.6M | -45.2M |
| Cash from investing | -149.8M | -12.2M | -30.5M | 27.3M | -84.9M | -19.8M | 18.6M | 57.1M | 99.6M | -113.7M |
| Cash from financing | 400.2M | 281.6M | 558.3M | 233.6M | 505.4M | 150.7M | 114.3M | -771.0K | -35.0M | -15.6M |
| Dividends paid | -616.0K | -334.4M | -4.44M | -2.28M | ||||||
| Share buybacks | -3.44M | -616.0K | 0 | 0 | -2.50M | -228.0K | -15.2M | -15.8M | ||
| Change in cash | -54.5M | -121.9M | 160.8M | -76.3M | 146.2M | -40.9M | -19.3M | -7.05M | 15.8M | -167.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| 8-K · Current report | Nov 9, 2026 | Current report | SEC |
| 8-K · Current report | Oct 14, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 2, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 6, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 4, 2026 | Quarterly report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Aug 4, 2026 | Results | SEC |
| 8-K · Current report | Jul 30, 2026 | Current report | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 30, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 10, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 8-K · Current report | May 18, 2026 | Material contract | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| 8-K · Current report | Apr 9, 2026 | Results | SEC |
| 8-K · Current report | Apr 6, 2026 | Current report | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 31, 2026 | Material contract | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 25, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 10-K · Annual report | Feb 23, 2026 | Annual report | SEC |
| 144 · Notice of proposed sale | Feb 23, 2026 | Other filings | SEC |
| 8-K · Current report | Feb 23, 2026 | Results | SEC |
| 8-K · Current report | Feb 18, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 26, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 16, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 15, 2026 | Results | SEC |
| 8-K · Current report | Jan 14, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Dec 23, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Dec 23, 2025 | Offer document | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 15, 2025 | Management or board change | SEC |
| 8-K · Current report | Dec 12, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 10, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 4, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2025 | Results | SEC |
| DEF 14C | Oct 20, 2025 | Meeting notice | SEC |
| PRE 14C | Oct 8, 2025 | Meeting notice | SEC |
| 8-K · Current report | Aug 8, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2025 | Results | SEC |
| 424B5 · Prospectus | Jul 28, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 25, 2025 | Results | SEC |
| S-8 · Registration statement for employee plans | Jun 23, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 20, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2025 | Results | SEC |
| 8-K · Current report | May 5, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 15, 2025 | Results | SEC |
| 424B5 · Prospectus | Apr 8, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 8, 2025 | Material contract | SEC |
| 8-K · Current report | Mar 19, 2025 | Current report | SEC |
| 10-K · Annual report | Mar 3, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 3, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 12, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Feb 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 7, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2024 | Insider trade | SEC |
| 424B5 · Prospectus | Dec 12, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 11, 2024 | Material contract | SEC |
| 8-K · Current report | Dec 10, 2024 | Current report | SEC |
| 424B5 · Prospectus | Dec 10, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 19, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jul 17, 2024 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Jun 20, 2024 | Offer document | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2024 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | May 3, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 30, 2024 | Other filings | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 29, 2024 | Annual report | SEC |
| 8-K · Current report | Apr 23, 2024 | Current report | SEC |
| S-3ASR · Registration statement | Apr 17, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Apr 3, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 28, 2024 | Other filings | SEC |
| S-3 · Registration statement | Mar 28, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 19, 2024 | Annual report | SEC |
| 4 · Change in ownership | Feb 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 23, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Feb 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jan 3, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 2, 2024 | Material contract | SEC |
| 4 · Change in ownership | Dec 19, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 8, 2023 | Quarterly report | SEC |
| DEF 14C | Sep 28, 2023 | Meeting notice | SEC |
| D | Sep 22, 2023 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 21, 2023 | Big-stake notice | SEC |
| PRE 14C | Sep 15, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | Sep 13, 2023 | Insider trade | SEC |
| 8-K · Current report | Sep 11, 2023 | Material contract | SEC |
| 4 · Change in ownership | Sep 6, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 6, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 6, 2023 | Insider trade | SEC |
| 8-K · Current report | Sep 1, 2023 | Current report | SEC |
| 4 · Change in ownership | Aug 28, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2023 | Insider trade | SEC |
| 8-K · Current report | Aug 15, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Aug 8, 2023 | Quarterly report | SEC |
| 424B5 · Prospectus | Jul 25, 2023 | Offer document | SEC |
| 424B5 · Prospectus | Jul 24, 2023 | Offer document | SEC |
| 8-K · Current report | Jul 21, 2023 | Material contract | SEC |
| 8-K · Current report | Jul 20, 2023 | Current report | SEC |
| 4 · Change in ownership | Jun 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 14, 2023 | Material contract | SEC |
| 4 · Change in ownership | Jun 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | May 22, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | May 16, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | May 11, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2023 | Current report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2023 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 28, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2023 | Material contract | SEC |
This page holds 200 of 557 filings. Open Filings
Cap table
Built by 6ix from ImmunityBio, Inc.’s releases · as of Nov 3, 2026
- Common shares
- 1,063,826,073
- Fully diluted
- 1,063,826,073
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 1,063,826,073 | Nov 3, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 3, 2026 | 1,063,826,073 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Bruce Wendel Other companies: GT Biopharma, Inc. (Director · Nov 11, 2020 – Jan 27, 2023 · Past); Verastem, Inc. (Director · Jun 14, 2016 – Jun 16, 2020 · Past); Abraxis BioScience Inc (Chief Executive Officer, Director · Nov 7, 2007 – Oct 15, 2010 · Past) | Director · Since at least Dec 12, 2025 |
| Barry Simon Other companies: Viracta Therapeutics Inc (Director · Mar 3, 2021 – Jun 20, 2024 · Past); Cue Biopharma, Inc. (Director · Jan 4, 2021 – Jan 4, 2021 · Past) | Director · Since at least Dec 22, 2020 |
| Robert Rosen Other companies: La Jolla Pharmaceutical Co (Director · Jul 7, 2014 – Aug 22, 2022 · Past); Heron Therapeutics, Inc. (President, Director · May 1, 2013 – Dec 15, 2018 · Past) | Director · Jul 27, 2015 – Jul 27, 2015 · Past |
| Sonja Nelson Other companies: Ambrx Biopharma Inc. (Chief Financial Officer · Jan 1, 2023 – Mar 7, 2024 · Past); Motus GI Holdings, Inc. (Director · Jun 22, 2021 – Mar 5, 2024 · Past) | Chief Financial Officer · Aug 2, 2019 – Jan 12, 2021 · Past |
| Cheryl L. Cohen Other companies: Celldex Therapeutics, Inc. (Director · Since at least Jun 13, 2024) | Director · Since at least Jun 11, 2024 |
| Linda Maxwell Other companies: United Therapeutics Corporation (Director · Since at least Jul 8, 2021) | Director · Since at least Mar 29, 2021 |
| Regan Lauer Other companies: Banc of California, Inc. (SVP - CONTROLLER · Dec 31, 2008 – Oct 23, 2012 · Past) | Chief Accounting Officer · Since at least Nov 9, 2021 |
| Wesley Clark Other companies: Blue Acquisition Corp. (Director · Since at least Jun 12, 2025) | Director · Since at least Jun 14, 2022 |
| Bruce Brown | Senior Vice President, Medical Affairs · Since at least Apr 21, 2025 |
| Charles G. Garlisi | Senior Vice President, Regulatory Affairs · Since at least Nov 5, 2026 |
All 28 people
| Person | Seat |
|---|---|
| Christobel Selecky | Director · Since at least Jun 29, 2026 |
| David Sachs | Chief Financial Officer · Since at least Nov 5, 2026 |
| Elizabeth Gabitzsch | Senior Vice President, Product Development & Vaccine Programs · Since at least Nov 5, 2026 |
| Emily Arison | Senior Vice President of Human Resources · Since at least Nov 5, 2026 |
| Enrique Diloné | Chief Technology Officer · Since at least Nov 5, 2026 |
| Hemanth Ramaprakash | Investor Relations · Since at least May 7, 2026 |
| Jim Yong Kim | Vice Chairman · Since at least Aug 10, 2026 |
| John Owen Brennan | Director · Mar 9, 2021 – Jun 11, 2024 · Past |
| Leonard S. Sender | Chief Medical Officer, Liquid Tumors & Cell Therapy · Since at least Nov 5, 2026 |
| Manju Saxena | Senior Vice President of Product Development, Cell Therapy Program · Since at least Nov 5, 2026 |
| Matthew Hilman | Vice President US Commercial – Urologic Oncology · Since at least Nov 5, 2026 |
| Michael Blaszyk | Director · Since at least Nov 5, 2026 |
| Patrick Soon-Shiong | Executive Chairman of the Board · Since at least Oct 21, 2026 |
| Rich Adcock | President & Chief Executive Officer · Since at least Jan 14, 2026 |
| Richard Adcock | CEO & President, Director · Since at least Dec 31, 2023 |
| Richard Kusserow | Director · Jun 9, 2017 – Jun 9, 2017 · Past |
| Sandeep Bobby Reddy | Chief Medical Officer · Since at least Apr 21, 2025 |
| Sarah Singleton | Chief Communications Officer & Head of Patient Advocacy · Since at least Oct 8, 2026 |
Log in to ask 6ix AI your own questions about ImmunityBio, Inc.